Neuralstem (CUR) Shares Jump 6% Following FDA Approval to Dose in Cervical Region
Tweet
Share
E-mailGet Alerts CUR Hot Sheet
Join SI Premium – FREE
Shares of Neuralstem (NYSE: CUR) up nearly 6 percent following news the company has received FDA approval to dose patients in cervical region in ongoing ALS trial.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Milestone Pharmaceuticals starts Phase 3 AFib-RVR trial for etripamil
- Korro Bio files ethics submission for urea cycle disorder drug trial
- FDA clears Implantica's RefluxStop implant for U.S. market
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
